Leading scientists have called for a moratorium on clinicalxenotransplantation "until ethical issues associated with the transfer of organs from animals to humans are resolved."
The call came just as the US National Institutes of Health began a two-day meeting last month, entitled Developing US Public Health Service Policy in Xenotransplantation, to propose tightening control over animal-to-human transplants. Fritz Bach, a researcher of xenotransplantation at Harvard University and a consultant to Novartis Pharma, joined six other public health experts and bioethicists in urging a moratorium.
The heightened interest in xenotransplantation stems from considerable advances in genetic engineering which makes it conceivable that the technology will become a reality.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze